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Abstract
Background: Ovarian cancer is the most deadly gynecological cancer with a very poor prognosis. Xenograft
mouse models have proven to be one very useful tool in testing candidate therapeutic agents and gene function
in vivo. In this study we identify genes and gene networks important for the efficacy of a pre-clinical anti-tumor
therapeutic, MT19c.
Methods: In order to understand how ovarian xenograft tumors may be growing and responding to anti-tumor
therapeutics, we used genome-wide mRNA expression and DNA copy number measurements to identify key
genes and pathways that may be critical for SKOV-3 xenograft tumor progression. We compared SKOV-3 xenografts
treated with the ergocalciferol derived, MT19c, to untreated tumors collected at multiple time points. Cell viability
assays were used to test the function of the PPARg agonist, Rosiglitazone, on SKOV-3 cell growth.
Results: These data indicate that a number of known survival and growth pathways including Notch signaling and
general apoptosis factors are differentially expressed in treated vs. untreated xenografts. As tumors grow, cell cycle
and DNA replication genes show increased expression, consistent with faster growth. The steroid nuclear receptor,
PPARg, was significantly up-regulated in MT19c treated xenografts. Surprisingly, stimulation of PPARg with
Rosiglitazone reduced the efficacy of MT19c and cisplatin suggesting that PPARg is regulating a survival pathway in
SKOV-3 cells. To identify which genes may be important for tumor growth and treatment response, we observed
that MT19c down-regulates some high copy number genes and stimulates expression of some low copy number
genes suggesting that these genes are particularly important for SKOV-3 xenograft growth and survival.
Conclusions: We have characterized the time dependent responses of ovarian xenograft tumors to the vitamin D
analog, MT19c. Our results suggest that PPARg promotes survival for some ovarian tumor cells. We propose that a
combination of regulated expression and copy number can identify genes that are likely important for
chemotherapy response. Our findings suggest a new approach to identify candidate genes that are critical for anti-
tumor therapy.
Background
Epithelial ovarian cancer (EOC) is the most lethal of all the
gynecologic cancers, affecting thousands of women each
year [1]. Most patients initially respond to chemotherapy,
only to recur within a few years with drug-resistant meta-
static disease [2]. Thus, there is a pressing need to develop
new anti-tumor therapies that can work alone, or in com-
bination with platinum-based therapy.
Two general approaches have been pursued to address
drug resistance: development of new therapeutics, and
drug combinations that improve standard platinum and/or
taxane based chemotherapy. The application of calcitriol/
vitamin D3 has emerged as an important strategy to target
the vitamin D receptor (VDR) for cancer treatment [3].
Hypercalcemia and other toxicities have limited develop-
ment of calcitriol and vitamin D analogs tested to date [3].
MT19c is a novel vitamin D analog based on B3CD [4,5]
that shows significant effects on EOC cell lines and xeno-
graft tumor models. MT19c was designed to be a vitamin
D receptor ligand but appears to work independently of
VDR (Brard L, Lange TS, Robinson K, Kim KK, Brodsky
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the first Ergocalciferol derived vitamin D receptor inde-
pendent true non-hypercalcemic anti-cancer agent
(MT19c), submitted). Here, we aimed to understand
which pathways and genes may be important for MT19c
action in a SKOV-3 xenograft tumor model. These data
also provide insight into key pathways and genes impor-
tant for tumor growth and survival.
As EOC progresses, tumors may evolve through two
general mechanisms: accumulation of new mutations, or
selection of specific cell types emerging from a heteroge-
neous mixture of cells [6]. In the clinic, examination of
tumors is typically only feasible as a snapshot at a given
time with little knowledge about how a tumor is evolving
during disease progression. A recent evaluation of long-
term platinum treatment of a mouse lung cancer model
suggested that DNA repair pathways are significantly up-
regulated leading to resistance [7].
Many mutations and chromosomal structural rearrange-
ments have been identified in primary ovarian tumors and
cell lines [8-10]. Copy number aberrations (CNAs) are a
common mechanism observed to control gene expression
and tumor progression [8]. Loss of DNA is another
mechanism that reduces expression of tumor suppressor
genes, which inhibit tumor progression. Conversely, DNA
copy number gain may increase expression of oncogenes.
However, CNAs can explain a significant fraction of the
v a r i a t i o ni ng e n ee x p r e s s i o n but not all of it, perhaps
because of epigenetic mechanisms such as DNA methyla-
tion [11,12].
The purpose of this study was to understand which
genes and pathways may be important for MT19c’sa n t i -
tumor activity and to identify genes critical for tumor pro-
gression. A number of genes in the PPARg network,
including PPARg, were enriched in MT19c treated tumors.
When PPARg is stimulated with Rosiglitazone, MT19c
and cisplatin have significantly higher IC50ss u g g e s t i n g
that PPARg is promoting survival in at least some types of
ovarian cancer cells, leading to poorer outcomes. By com-
bining CNAs and drug induced expression changes, we
observe a subset of genes that may be particularly impor-
tant for MT19c action and/or tumor survival. We propose
that combining copy number analysis with drug induced
expression changes can identify key genes important for
chemotherapeutic efficacy. These results will be relevant
to plan future xenograft studies and highlight the impor-
tance of considering the changing tumor dynamics over
time when evaluating gene expression and drug responses.
Methods
Cell culture and Reagents
SKOV-3 (ATCC) cells were grown DMEM (Mediatech,
Manassas, VA) with 10% FBS (Hyclone, Logan, UT) with.
MT19c was synthesized as described in detail elsewhere
[13]. Briefly, commercially available Ergocalciferol under-
went a Diels-Alder reaction with N-methyl,1,2,4-triazoline-
dione to generate an adduct, which upon reaction with
bromoacetic acid in the presence of DCC (N, N’-dicyclo-
hexylcarbodiimide) generated MT19c in good yields. Rosi-
glitazone was purchased from Axxora (San Diego, CA).
GW9662 was purchased from Sigma-Aldrich (St Louis,
MO).
SKOV-3 Xenograft Tumors and Treatment
SKOV-3 cells (2 × 10
6 cells/inoculate) were suspended in
0.1 mL of matrigel and inoculated subcutaneously in the
flank of 4-6 week-old nude mice (NU/NU; strain code
088/homozygous) (Charles River Laboratories, Wilming-
ton, MA) two weeks before treatment. MT19c was pre-
pared as a stock solution of 1 mM in 100% EtOH and
diluted 1:40 in PBS for administration. Mice were moni-
tored and treated intraperitoneally (IP) every other day
with either vehicle control (control group, PBS/2.5%
EtOH; 12 animals) or 0.3 mL (10 mg/kg bwt) of MT19c
(10 animals). Tumor size was calculated using a caliper.
Animal experiments were carried out in the animal facil-
ities of Rhode Island Hospital (RIH), RI, USA with strict
adherence to the guidelines of the Animal Welfare Com-
mittee of RIH and Women and Infants Hospital (IACUC
protocol # 0061-07).
RNA purification and microarrays
RNA was isolated from each tumor by homogenization in
Trizol (Invitrogen) using a Tissuemizer (Tekmar Company,
Cincinnati, OH). RNA was purified using Qiagen RNAsy
columns following manufacturer’s protocol. All RNA was
of high quality as assessed by an Agilent 2100 Bioanalyzer
(Agilent Technologies, Inc. Santa Clara, CA). RNA was
prepared for hybridization on Affymetrix Human Gene 1.0
St arrays. All RNA processing, array hybridizations and
scanning were performed by the Brown University Center
for Genomics and Proteomics core facility. RNA was pre-
pared for hybridization using Affymetrix standard proto-
cols and applied to Human Gene 1.0 ST microarrays
(Affymetrix, Santa Clara, CA). All microarrays were quan-
tile normalized together and the Probe Logarithmic Inten-
sity Error (PLIER) algorithm was used to generate signal
estimates for all RefSeq genes. To select actual signal, we
discarded those transcripts belonging to the lowest quartile
of their respective datasets. Analysis of significantly chan-
ging genes was determined using R http://www.r-project.
org/. Complete microarray data have been deposited at the
National Center for Biotechnology Information’sG e n e
Expression Omnibus (accession number GSE23616).
Ingenuity Pathway Analysis
The discriminating genes were used as input into Inge-
nuity Pathway Analysis (IPA) (Ingenuity IP 8.6-3003
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tings were used, the Ingenuity Knowledge database for
genes on the Affymetrix Human Gene 1.0 St Array was
used as a reference set, direct and indirect relationships
were included, with a maximum of 35 molecules per
network and a maximum of 25 networks per analysis.
All data sources and species, and all tissues and cell
lines were included. IPA uses a Fischer’s exact test to
determine which pathways and biological functions are
significantly enriched in the input gene set relative to
the reference set.
Quantitative Real-Time PCR
Equal amounts of total RNA were reverse transcribed
using Superscript III and random hexamers (Invitrogen,
Carlsbad, CA). Resulting cDNA was renormalized using
Quant-iT PicoGreen (Invitrogen) before mixing with 1×
Power SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster City, CA). Reactions were performed in an
Applied Biosystems 7900HT Fast Real-Time PCR Sys-
tem. The fold change was calculated as described pre-
viously using calnexin as an internal control. Primer
sequences are listed in Additional file 1 Table S1.
DNA purification and CGH arrays
DNA was isolated using Qiagen DNasy Blood and Tis-
sue Kit following manufacturer’s instructions. DNA
quality was determined on an agarose gel as shown in
Figure 1. DNA was prepared for Agilent 180 K CGH
microarrays using the Roche NimblGen (Madison, WI)
enzymatic labeling protocol using random nonamers
and hybridized following manufacturer’s protocols at the
Microarray Centre at the Prostate Centre in Vancouver,
British Columbia, Canada. Each sample was hybridized
with Promega (Madison, WI) female reference DNA.
The log10 copy number ratios were smoothed using a
standard deviation-based outlier detection method and
segmented using Circular Binary Segmentation (CBS)
[14] as implemented in the R package DNAcopy
(’smooth.region = 10’ for the smoothing method, ‘alpha
=0 . 0 5 ’ for the segmentation, and default parameters for
all other arguments). A log10 copy number for each
gene was computed by averaging the smoothed and seg-
mented log10 ratios for each probe located in within the
gene region. Only genes that contained three or more
probes were considered.
Cell viability measurements
Cells were plated in 96-well plates and, 24 hours later,
were treated with the indicated combinations of com-
pounds. Viability was measured after 96 hours by WST-
1 (Roche). All assays were done in biological triplicate,
with technical triplicates done for each biological repeat.
Results
Experimental design
To understand the genes and pathways that drive tumor
growth and drug response, we compared MT19c and
vehicle treated SKOV-3 xenografts in nude mice.
SKOV-3 expresses VDR (Additional file 2 Figure S1)
and is a common cell line to model EOC. We aimed to
understand how a tumor evolves during treatment com-
pared to untreated, growing tumors. Measurements of
tumor size revealed that MT19c significantly reduced
tumor size or limited growth (Figure 1A and 1B). Past
experiments with larger numbers of mice show more
statistically significant MT19c effects [15,16]. MT19c
induced DNA degradation, consistent with apoptosis,
further demonstrating MT19c’s anti-tumor activity (Fig-
ure 1C). MT19c is known to induce apoptosis in the
SKOV-3 cell line [15,16]. Xenograft tumors were col-
lected at multiple time points after the initiation of
treatment as indicated by the labels where the first letter
indicates the treatment (T for MT19c and N for naïve),
the number indicates the number of days, and the final
letter indicates the replicate. For example, T8A indicates
the A replicate of an 8 day MT19c treated tumor.
The T16C xenograft tumor has a notably different
MT19c response compared to the other tumors. T16C
appeared to grow before rapidly shrinking. Upon collec-
tion, T16C appeared to have a liquid center, which may
indicate necrosis. The DNA from T16C was significantly
degraded as shown in Figure 1C. Thus, MT19c appears
to repress the T16C xenograft tumor effectively but dif-
ferently than the other tumors. The naïve tumor, N16A,
appeared not to have grown significantly during the
experiment. However, clustering and other expression
behaviors indicate that this xenograft tumor is more
similar to the other naïve tumors compared to the
MT19c treated tumors. In addition, H&E staining indi-
cated that each xenograft tumor was not significantly
infiltrated with vascularization (Additional file 3 Figure
S2). Together, these observations suggest that MT19c is
an effective anti-tumor molecule and that the majority
of the purified nucleic acids were derived from human
tumor cells in this xenograft system.
MT19c induced gene expression changes
To identify genes and pathways that are differentially
expressed upon MT19c treatment and tumor progres-
sion, we took a genome-wide approach. RNA was puri-
fied from each tumor and probed with Affymetrix
Human Gene St 1.0 microarrays.
To determine which tumors are most alike, the top
75% of all expressed genes were hierarchically clustered
using Hierarchical Clustering Explorer (HCE). Tumors
collected after treatment initiation do not clearly separate
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time points, T28 and T32, are in the same clusters with
the other time points suggesting that time was not the
defining factor. However, the tumors can be classified
into distinct clusters based on treatment when the long
time points, T28 and T32, are removed (Figure 2B). The
treated and control tumors cluster together except for
T16C which appears to be an outlier in its expression
profile, growth curve and was very necrotic, with a liquid
middle not apparent in the other tumors T16C also had
a distinct growth profile, highlighted by rapid increase
followed by a sharp decrease in tumor size (Figure 1B).
We therefore thought it reasonable to exclude T16C to
identify key genes involved in MT19c action.
Because the tumors collected at longer times appear
to be outliers from the clustering analysis, we focused
on the first two time points to assess treatment-depen-
dent and time-dependent changes. To gain insight into
consistent MT19c induced effects, we compared the
treated and naïve tumors from the first two time points,
days 8 and 16, excluding the T16C outlier. We identified
the most significantly MT19c regulated transcripts by a
t-test (q < 0.05) and log2 fold change > 0.6 (Additional
files 4 and 5, Tables S2 and S3). MT19c up-regulated
268 and down-regulated 306 genes when comparing the
six naïve tumors from the 8 day and 16 day time points
to the five MT19c treated tumors from the same time
points that clustered similarly (T8A, T8B, T8C, T16A,
T16B) (Figure 2). To validate the data, we sampled
genes by real-time qPCR and found good concordance
in trend but not magnitude (Additional file 6 Figure S3).
This is a common observation when comparing micro-
array and qPCR data, where the microarray dynamic
range is reduced compared to qPCR [17].
MT19c regulated pathways
To gain insight into MT19c regulated pathways, we
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Figure 1 MT19c reduces growth of SKOV-3 xenograft tumors and induces apoptosis. A. MT19c significantly reduced the growth of
xenograft tumors on average. The size of each tumor was measured with calipers, average for each time point and plotted. Error bars are
standard deviations of the mean tumor measurements. B. Individual growth curves for the naïve (N16A, B, C) and MT19c treated (T16A, B, C)
xenograft tumors C. Purified DNA reveals MT19c induced degradation of DNA. One μg of DNA from each specimen was purified and run on an
agarose gel. All MT19c treated tumors had significantly degraded DNA while the majority of the DNA from naïve tumors is in a distinct upper
band indicative of high molecular weight DNA.
Stuckey et al. BMC Cancer 2011, 11:308
http://www.biomedcentral.com/1471-2407/11/308
Page 4 of 13enriched pathways mediated by MT19c and tumor pro-
gression over time. GSEA uses all Refseq transcripts on
the microarray data to identify biases in tested pathways
between two conditions [18]. Table 1 summarizes path-
ways enriched in treated vs. naïve tumors. Energy meta-
bolism genes including transcripts coding for oxidative
phosphorylation machinery were down-regulated by
MT19c compared to naïve tumors. These metabolic
pathways may be higher in the naïve tumors because
these tumors may have been growing faster and were
therefore more metabolically active. On the other hand,
genes involved in double strand break repair, protein
turnover, and apoptosis were enriched in MT19c treated
tumors. The double strand break repair pathway is high-
lighted by stimulation of XRCC4, RAD54B and RAD50
as show in Figure 3. These protein products are thought
to directly repair DNA and not just be part of a general
stress response. Stimulation of DNA repair pathways
may help tumor cells survive the lethal effects of MT19c
or, alternatively, MT19c may be inducing DNA damage
to elicit this response. Grouping the MT19c treated and
naïve tumors identified numerous pathways and genes
differentially regulated.
Specific time dependent changes may be observed by
examining each time point separately as opposed to
grouping the treated and naïve tumors. Comparing day
8 treated to the day 8 naïve tumors, we observed down-
regulation of genes in cell cycle control, DNA replication,
Eϴ Eϴ EϯϮ dϮϴ EϭϲEϭϲEϭϲEϴ dϴ dϴ dϭϲ dϴ dϭϲ dϯϮ dϭϲ
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Figure 2 Hierarchical clustering of mRNA expression in each tumor suggests MT19c treatment is the defining feature of the panel of
xenograft tumors. A. All samples were clustered by HCE Hierarchical Clustering Explorer revealing four major groups. Outliers are in black. B.
Tumors collected after 16 days were removed from the clustering revealing two distinct classes defined by MT19c treatment.
Table 1 Gene Set Enrichment Analysis reveals MT19C
down-regulation of energy metabolism and stimulation
of DNA repair and apoptosis pathways
Geneset NES P-value FDR GSEA
Kegg (n = 165)
Cell Communication -1.97 0.000 0.029
Biosynthesis of Steroids -1.95 0.002 0.046
Galactose metabolism -1.84 0.005 0.082
Oxidative Phosphorylation -1.69 0.000 0.102
Notch signaling pathway -1.49 0.032 0.232
Ubiquitin mediated Proteolysis 1.98 0.000 0.021
Gene Ontology (n = 1307)
Double Strand Break Repair 1.86 (1.85) 0.000 (0.006) 0.006
Ubiquitin Cycle 2.01 (1.96) 0.000 (0.000) 0.111
NES > 1.4 indicates enriched in MT19C treated tumors compared to naïve
tumors for all 8 and 16 day tumors, including T16C.
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On the other hand, comparing day 16 treated and naïve
tumors revealed up-regulation of protein synthesis
machinery (Table 3). These data indicate that MT19c initi-
ally affects tumor growth. The cell cycle pathway enriched
in day 8 treated vs. day 8 naïve tumors is highlighted by
CCNE2, a cyclin that peaks during G1-S phase transition
[19]. This is consistent with the MT19c induced cell cycle
arrest [13]. At later times, translation factors and protein
synthesis machinery are up-regulated by MT19c perhaps
reflecting the tumor’s attempts to try to survive by up-reg-
ulating other genes at the translational level.
Consistent with the enriched cell cycle pathways, genes
regulated by E2Fs were also expressed at higher levels in
treated tumors compared to naïve tumors. E2Fs are key
transcription factor regulators of the cell cycle, especially
the G1-S transition [20]. However, at later times, neither
E2F regulated genes nor cell cycle associated genes
including CCNE2 were significantly different between the
treated and control tumors. This suggests that rapid,
initial changes on proliferation and cell cycle regulators
are induced by MT19c. Moreover, these observations
suggest that tumors collected at different time points
reflect specific responses to MT19c.
PPARg Activity Enhances SKOV-3 Survival
Extrapolating the function of genes from gene expression
data is complicated by the observation that genetic back-
ground can determine whether a gene is behaving as an
oncogene or tumor suppressor [21]. Moreover, multiple
interpretations are often consistent with the observed
gene expression changes. For example, increased expres-
sion from a therapeutic drug may be part of tumor cells’
attempt to try to survive the stress or the gene may be
directly stimulated to induce cell death. Steroid nuclear
receptors are well-known druggable targets that often
regulate cell fate [22,23] whose functional role can be
rapidly tested with small molecule ligands. We observed
that PPARg itself is significantly stimulated by MT19c.
Selecting the top MT19c regulated genes at day 16, (p <
0.05, Fc > 1.4), we observed an extensive network of
regulated genes centered around PPARg in the top scor-
ing network using Ingenuity Pathway Analysis (IPA)
(Figure 4A). These data suggest that PPARg and asso-
ciated genes were stimulated by MT19c signifying
increased PPARg function. MT19c stimulated genes may
be part of the MT19c response or may be part of a survi-
val response as the cells try to stay alive in the presence
of a cytotoxic agent. Previous studies suggested that the
PPARg agonist, Rosiglitazone, inhibited ovarian cancer
cell growth and enhanced cisplatin therapy [24]. To test
PPARg’s role in the chemotherapeutic response of
MT19c, we measured the effect of Rosiglitazone on
SKOV-3 cell viability when treated in combination with
MT19c. Figure 4B shows that Rosiglitazone increases the
MT19c IC50 from about 2 to 4 μM. We observed similar
effects with combinations of Rosiglitazone and cisplatin
suggesting that the PPARg pathway is likely a general sur-
vival pathway, and not specific for MT19c activity (Addi-
tional File 7, Figure S4). Stimulating PPARg appears to
induce a survival response in SKOV-3 cells suggesting
that the observed increased expression of PPARg is likely
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Figure 3 Genes associated with double strand break repair are up-regulated by MT19c. Enrichment plot of the double strand break repair
gene set identified by GSEA and corresponding heat map for MT19c and naïve tumors. Expression level is represented as a gradient from high
(red) to low (blue).
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activity. We then tested a PPARg antagonist, GW9662,
which did not significantly affect cells as a single agent or
in combination with MT19c until very high concentra-
tions (Additional File 7, Figure S4). This suggests that
inhibiting PPARg activity does not necessarily induce cell
death. Unlike published studies in other cell lines [24],
Rosiglitazone does not appear to significantly affect
SKOV-3 proliferation. To test how Rosiglitazone may
mediate cisplatin efficacy in other cell lines, we tested
combinations of these two molecules in the other NCI60
ovarian cancer cell lines (Figure 4B and Additional File 8,
Figure S5). Three cell lines (OVCAR-3, OVCAR-5, and
OVCAR-8) showed modest, but reproducible, 20%
decreases in cell viability after four days of Rosiglitazone
treatment while two others (IGROV-1 and OVCAR-4)
showed no significant effects. Thus, SKOV-3 may be a
special case, where Rosiglitazone inhibits cisplatin activity
and stimulates survival. Like many factors, the genetic
background appears to control whether a gene is acting
as an oncogene or tumor suppressor [21,25]. These
observations highlight how the same factors may lead to
opposite functions to control growth and survival in var-
ious subtypes of ovarian cancer.
A second IPA identified network, centered on insulin
(Figure 4C), is observed when comparing all the naïve
and MT19c treated tumors. These observations may be
consistent with findings suggesting that IRS 1/2 and
ERK 1/2 pathways are down-regulated by MT19c [13].
These expression data along with probing of insulin sig-
naling in cell culture, suggest that MT19c is down-regu-
lating these pro-growth and survival pathways in SKOV-
3 as part of its anti-tumor activity.
MT19c Regulates Genes in Copy Number Aberrations
Copy number changes often drive gene expression of key
factors critical for tumor survival and growth. We
Table 2 Increased expression of cell cycle regulators as
during naïve tumor growth by GSEA
Geneset NES P-value FDR GSEA
Naïve Tumor 8 day vs. 16 day
BioCarta (n = 184)
Cell cycle pathway -2.06 0.000 0.065
Kegg (n = 165)
Ribosome 2.25 0.000 0.000
Cell Cycle -2.34 0.000 0.000
Proteasome -1.72 0.000 0.088
GenMapp (n = 107)
DNA replication reactome -2.13 0.000 0.003
Cholesterol Biosynthesis -1.89 0.012 0.024
TFT (n = 614)
E2F_Q3 -1.84 0.000 0.039
E2F1_Q6 -1.76 0.000 0.027
Gene Ontology (n = 1307)
M phase of mitotic cell cycle -2.15 0.000 0.008
M phase -2.17 0.000 0.007
Mitosis -2.18 0.000 0.008
MT19C 8 day vs. 16 day
GenMapp (n = 107)
DNA Replication Reactome 1.74 0.000 0.056
Ribosomal Proteins -2.44 0.000 0.000
Proteasome -1.76 0.016 0.091
Kegg (n = 165)
Cell Cycle 1.68 0.004
Apoptosis -1.54 0.016 0.164
Transcription Factor Targets (n = 614)
E2F_Q4 1.83 0.000 0.025
E2F1_Q6 1.77 0.000 0.018
NFKB -1.79 0.000 0.021
AP1 -1.78 0.000 0.024
NFKAPPAB -1.52 0.000 0.063
NES > 1.4 indicates higher expression in 8 day naïve tumors compared to 16
day. NES < -1.4 indicates higher expression in 16 day naïve tumors compared
to 8 day.
Table 3 Cell cycle regulators are more affected by MT19C
at earlier times while translation regulators and
ribosomes are affected at later times by GSEA
Geneset NES P-value FDR
Treat8 vs. Naive8
Biocarta (n = 184)
ATRBRCA pathway 1.74 0.000 0.315
MTA3 pathway -1.87 0.000 0.141
GenMapp (n = 107)
DNA Replication 1.84 0.000 0.024
G1 to S Cell Cycle Reactome 1.59 0.006 0.122
Krebs TCA Cycle 1.49 0.033 0.219
Galactose metabolism -1.88 0.000 0.113
Oxidative Phosphorylation -1.68 0.002 0.139
Nuclear Receptors -1.59 0.013 0.227
Kegg (n = 165)
Cell Cycle 1.94 0.000 0.013
Transcription factor targets (n = 614)
E2F1s 1.76-2.05 0.000 0.000-0.008
Bach2 -1.73 0.000 0.037
Treat16 vs. Naive16
Genmapp (n = 107)
Ribosomal proteins 2.41 0.000 0.000
Aminoacyl tRNA biosynthesis 2.05 0.002 0.003
Translation Factors 1.66 0.005 0.203
Comparisons are indicated byTreat8 vs. Naive8 and Treat16 vs. Naive 16. NES
> 0 indicates higher expression in MT19C treated tumors and NES < 0
indicates higher expression in naïve tumors.
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select cells that can evade induced cell death, drive faster
growth, and directly affect gene expression through gene
dosage effects. We initially observed that GSEA analysis
suggested a number of genomic loci were significantly
up- and down-regulated by MT19c (Additional Files 9
and 10, Tables S4 and S5). We hypothesized that these
MT19c induced changes could be due to the type of
tumor cell selected by MT19c compared to naïve tumors.
To test this possibility, we performed CGH analysis by
purifying DNA from each tumor. DNA was competitively
hybridized to Agilent 180 K microarrays with pooled
female DNA. For the most degraded treated samples, day
30 xenograft tumors, the microarray signal was poor and
was not considered further. The Agilent arrays were seg-
mented using circular binary segmentation (CBS), after
outliers greater than four standard deviations from the
neighborhood of 20 probes were removed. Each tumor
had similar copy number patterns suggesting the same
genomes were selected to form the xenografts, with only
relatively subtle difference such as in 17 p and 7 p (Addi-
tional File 11, Figure S5). Perhaps because of the small
number of tumors and the observation that 3/8 MT19c
tumors retain some copy loss, no significant trend in
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number of viable cells. C. Insulin centered network identified by IPA. Red indicates stimulated by MT19c and green indicates down regulation by
MT19c. Ingenuity Pathway Analysis (IPA) of significantly up and down MT19c (Fold change > 1.4, p < 0.05) regulated genes comparing 16 day
treated and naïve tumors identifies a network centered around insulin regulation.
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Page 8 of 13expression change for these genes between the treated
and naïve tumors is observed.
Copy number can be a major determinant of expres-
sion levels for some genes. To determine if gene dosage
drives expression of some genes in these xenografts, we
mapped segmented CGH probes to each RefSeq gene,
to determine a log score reflecting its copy number sta-
tus. This score was calculated by averaging the log10
copy number ratios of the probes within each gene and
selecting transcripts in the top quartile of all expressed
g e n e s .Ag l o b a lv i e wo fS K O V - 3C N A ss h o wam o d e s t
number CNAs compared to other cell lines (Additional
File 11, Figure S5) [26].
Because CNAs in tumors are often very large, many
genes may be affected by the change in copy number,
complicating determination of the functional importance
of these genes. We reasoned that genes that are function-
ally important in CNAs would be differentially affected by
an anti-tumor agent. To test if genes in CNAs are differen-
tially regulated by MT19c, we created gene sets including
all genes with log ratios > 0.3 in the gene set and expres-
sion levels consistent with being regulated by copy num-
ber (Additional File 12, Table S6). Using GSEA, these
CNA gene sets revealed that MT19c down-regulated
amplified genes and up-regulated genes in copy loss
regions (Figure 5A), consistent with the idea that many of
these genes are likely important for tumor cell growth and
survival. qPCR of selected genes suggests the validity of
this approach (Figure 5B). For example, a number of genes
that may be important for growth and survival are signifi-
cantly down-regulated by MT19c despite having high copy
numbers, including histones (HIST1H3B, HISTH2AE and
HIST1H4L), a key enzyme in fatty acid metabolism (DCI),
and cell surface proteins possibly important in cell-cell
interactions (AGRN, GRN). In particular, the chr17 region
including PNMT, ERBB2, and nearby genes such as GRN,
is amplified and many of the genes are down-regulated by
MT19c. This region is amplified in numerous ovarian can-
cer cell lines including OVCAR-3, OVCAR-5, OVCAR-8,
and CAOV-3 [26] and in a small population of ovarian
tumors, although targeting Her2 (ERBB2) has not been
successful to date in EOC [27,28]. We observe a number
of genes being down-regulated including PNMT, which
catalyzes a key step in epinephrine synthesis. Epinephrine
may be stimulating tumor growth of ovarian cancer cells,
including SKOV-3 [29] and appears to be more sensitive
to MT19c action than other genes in this region. These
observations suggest that other genes near the ERBB2
locus may also be important for tumor progression and
MT19c response.
Many of the copy loss regions span large segments of
chromosomes (Additional File 11, Figure S5), signifi-
cantly complicating the identification of important
genes. MT19c up-regulates some genes in copy loss
regions (Figure 5). By reducing the number of genes
that are expressed and change expression, we have
reduced the number of candidates to consider for
further experimentation and importance. The up-regula-
tion of these genes when challenged with MT19c, sug-
gests that they may be important to inhibit growth.
Discussion
Xenograft tumor model systems are powerful tools for the
evaluation and development of anti-tumor therapeutics.
These models are especially useful for ovarian cancer,
where only limited mouse models have been developed
[30]. SKOV-3 ovarian cancer cells are one of the more
commonly used cell lines to model ovarian cancer. We
a i m e dt ou n d e r s t a n dw h a tm a yd r i v ex e n o g r a f tt u m o r
growth, which likely differs from growth in cell culture
conditions, and what factors may be important for anti-
tumor treatment. As a model, we tested the effects of
MT19c, a vitamin D derivative that shows promising pre-
clinical properties as demonstrated here and elsewhere
[6,15,16]. We used multiple approaches to identify signifi-
cantly MT19c regulated genes, pathways and networks
with experimental support suggesting the functional
importance of the insulin and PPARg networks for MT19c
efficacy. In particular, we found that PPARg and PPARg-
controlled networks are up-regulated in treated tumors
and stimulation of PPARg with Rosiglitazone inhibited the
chemotherapeutic efficacy in SKOV-3 cells. Finally, we
propose an approach integrating copy number and expres-
sion data to identify which genes within CNAs are most
likely to be important for tumor progression and che-
motherapy. We propose that genes with high or low copy
number, along with significant gene expression changes in
response to an anti-tumor agent indicate genes important
tumorigenesis.
This approach of linking copy number and drug induced
expression changes may be a viable approach to identify
particularly important genes for tumor progression.
Although the majority of high copy number and high
expression genes were affected by MT19c, many were not.
A few high copy number genes such as RPL23 and RPS29
were significantly stimulated by MT19c. These high copy
number genes may be up-regulated to help SKOV-3 cells
survive in response to a lethal compound such as MT19c.
But, their up-regulation upon MT19c treatment suggests
that their high expression and high copy number may be
serving a different role than down-regulated genes. Com-
bining gene expression and copy number can reduce the
number of genes to consider for further study. These data
also suggest that genes regulated by dosage play an impor-
tant role in cancer cells’ response to chemotherapy.
Together, these data provide insights into general path-
ways important for tumor progression and survival as well
as MT19c efficacy.
Stuckey et al. BMC Cancer 2011, 11:308
http://www.biomedcentral.com/1471-2407/11/308
Page 9 of 13Our observations suggest that in some cases the PPARg
network is stimulated to help ovarian cancer cells survive
as suggested by Rosiglitazone treatment increasing the
IC50s of MT19c and cisplatin. The observations suggest
that stimulation of PPARg by Rosiglitazone increases
SKOV-3 chemotherapy resistance (Figure 4B). Rosiglita-
zone has been reported to inhibit growth and enhance cis-
platin efficacy in some ovarian cancer cell lines, though
SKOV-3 was not tested [24]. These findings suggest that
additional study is warranted to understand the conditions
in which Rosiglitazone may be an effective chemothera-
peutic and when it may actually promote survival of ovar-
ian cancer cells.
We aimed to understand which gene expression net-
works may be important for SKOV-3 xenograft tumors
progression and MT19c response. We found that signifi-
cantly different conclusions may be made depending on
how long the tumor was treated before the specimen was
collected. Because xenograft tumors, much like patient
tumors, are continuously evolving during growth, drug
responses may differ at each captured state of the tumor
at the time the specimen is collected for analysis. Genes
involved in the cell cycle, energy metabolism, and DNA
replication machinery are significantly affected by MT19c
at the earlier, day 8 time point, while regulation of protein
synthesis and ribosomes were significantly up-regulated at
ŽƉǇ'ĂŝŶ'ĞŶĞƐ
E^сͲϮ͘ϰϭ͕ƉфϬ͘ϬϬϭ͕&ZфϬ͘ϬϬϭ
ŽƉǇ>ŽƐƐ'ĞŶĞƐ
E^сϭ͘ϱϰ͕WфϬ͘ϬϬϭ͕&ZсϬ͘ϬϬϰ
Higher in Naive Higher in MT19c
B
E
n
r
i
c
h
m
e
n
t
 
S
c
o
r
e
 
(
E
S
)
E
n
r
i
c
h
m
e
n
t
 
S
c
o
r
e
 
(
E
S
)
Copy Gain
Copy Loss
A
qPCR Log2 Fc (Mt19c/Vehicle)
A
r
r
a
y
 
L
o
g
2
 
F
c
(
M
t
1
9
c
/
V
e
h
i
c
l
e
)
Figure 5 Genes in copy number gain or loss regions mediate gene expression and are significantly affected by MT19c treatment. A. GSEA
Enrichment plots suggest that amplified genes are significantly down-regulated by MT19c compared to naïve tumors while copy number loss genes
are significantly up-regulated by MT19c. Significantly amplified (log ratio > 0.3) or deleted genes (log ratio < -0.3) with concomitant high or low
expression were selected to define the gene sets. The black lines demonstrate where each gene in the gene set falls within the 15,000 probe sets
probing RefSeq transcripts ordered from left to right based on the expression level in MT19c treated or naïve tumors with gene #1 the most highly
expressed in MT19c treated tumors. The green line represents the running ES score that becomes more negative as probe sets are identified toward
the bottom of the list. More black lines are observed near the top of the rankings in untreated tumors (right side) than in the treated tumors (left side)
for amplified genes while genes in LOH regions are biased towards treated tumors (right side). The genes that are most significantly affected by
MT19c may be the most important genes mediating SKOV-3 tumor growth and survival. B. qPCR of selected genes within CNAs validates microarray
observations. Copy loss genes include PBEF1, STEAP1, and ZNF32. Copy gain genes are PNMT, GRN, PAPLN, and SLC25A6.
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Page 10 of 13the later day 16 time point. No significant enrichment of
cell cycle and DNA replication machinery was observed
after 16 days of MT19c treatment. These pathways are
often observed to be affected in tumors as control of meta-
bolism and the cell cycle are often critical for tumor
growth and survival. From gene expression data, it is diffi-
cult to conclude whether the effects are direct or indirect.
These data identify candidate genes to test for their impor-
tance in mediating chemosensitivity in ovarian cancer cells
as well as possible specific factors related to MT19c that
can be discriminated with further study.
A significant contribution to these differences appears
to originate from changes in the tumor as it progresses.
This is highlighted when comparing the naïve tumors at
the day 8 and 16 time points. When comparing the day
8 and 16 naïve tumors, cell cycle and DNA replication
machinery is expressed higher at later times. We then
observed that MT19c down-regulates the cell cycle at
early times and yet not at later times when many of
these genes are expressed at higher levels. Many of
these genes are controlled by E2F. These observations
suggest that control of the cell cycle depends on when
the tumor is collected. In patients, the exact place in
tumor progression/growth is always different and thus
this alone can explain expression differences, as opposed
to the inherent character of genomic differences of the
tumor. Among many other factors, these expression
changes during tumor growth may be inherent to
tumors and could be a source of heterogeneity in
patient samples. In probing xenograft tumors, these
observations highlight the importance of examining
changes at multiple time points, and not just at an arbi-
trarily defined endpoint.
Integrating copy number and expression measurements
has proven valuable to gain insight into tumor networks
and regulation [31]. However, determining which genes
are drivers of tumorigenesis and which may be passengers
remains a challenging problem, typically requiring exten-
sive experiments to test the function of identified factors
[32]. Copy number can be a mechanism driving gene
expression levels. Typically this is assessed by correlating
the measured expression and copy number values. Here,
we propose an extension of the copy number and expres-
sion comparison, in which we identify important genes in
CNAs by examining changes driven by an anti-tumor
therapy such as MT19c. Alternatively, these expression
changes could also indicate chromatin deregulation of
these genes, suggesting that the observed differential regu-
lation is simply a result of chance. The many loci differen-
tially regulated by MT19c suggest extensive changes in
epigenetic control by MT19c. We believe the simplest
explanation is that the MT19c induced down-regulation
strongly suggests that at least some of these amplified
genes are important for growth.
Together, these observations suggest that some of the
amplified genes are important for tumorigenesis consis-
tent with the hypothesis that amplified genes are selected
for tumor growth and survival. Similarly, genes at lower
gene dosage are stimulated by MT19c to induce cell
death or at least limit growth. These observations suggest
that a significant fraction of these CNA genes are impor-
tant for tumor growth and survival. We speculate that
these loci are being deregulated epigenetically by chro-
matin changes to overcome the gene dosage determined
by the DNA copy number at the time points tested.
Thus, the combination of DNA copy number and the
mRNA expression behavior in response to MT19c sug-
gest that these genes may be among the most important
for SKOV-3 xenograft progression.
MT19c has strong anti-tumor effects in multiple ovar-
ian cancer cell lines including SKOV-3; however, the
mechanism of MT19c action remains unclear. We
observed many factors and pathways affected by MT19c,
including some related to tumor growth and survival,
such as DNA damage response, apopotic genes, insulin,
and PPARg. Similar to PPARg, it is likely that many of
these factors are general survival and pathway factors for
SKOV-3 cells. Identifying specific mechanisms from
expression data based on small molecule perturbations
remains challenging, and requires significant additional
functional studies. These data highlight how MT19c
affects specific pathways, such as PPARg and insulin sig-
naling, that can be tested in additional cell lines and in
vivo models to determine their importance. These studies
could lead to the development of biomarkers to help
determine which features effect MT19c efficacy in pre-
clinical and clinical models.
Combining copy number and changes in gene expres-
sion approach in multiple cell lines may prove useful to
identify particularly important genes in mediating survi-
val and drug responses in ovarian cancer. The major
copy number changes in the SKOV3 xenografts are
observed in the SKOV-3 cell line as reported [26]
including the amplifications on chromosomes 3 and 17
and LOH on chromosome 1.
Conclusions
In summary, these data characterize SKOV-3 ovarian
xenograft tumors and identify candidate factors important
for tumor progression and response to chemotherapy. We
have characterized the time dependent expression changes
of SKOV-3 xenograft tumors in response to a novel che-
motherapeutic. We also identify a possible role for PPARg
and Rosiglitazone stimulation in mediating chemotherapy
in some ovarian cancer cells. Further study examining the
widely varying functions of PPARg in different genetic and
epigenetic backgrounds is warranted. Finally, we propose a
new integrated genomics approach that combines copy
Stuckey et al. BMC Cancer 2011, 11:308
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Page 11 of 13number and expression data to identify candidate tumor
drivers. We find a general bias for down-regulation of
amplified genes by the cytotoxic agent, MT19c, high-
lighted by strong down-regulation of genes, such as
PNMT, in the same amplicon as the ERBB2 locus. These
observations suggest that at least some genes regulated by
dosage are critical for chemotherapy responses. Together,
these data suggest that integrated genomics can provide
important insights into the behavior of xenograft tumor
systems, which are commonly used to evaluate tumor pro-
gression and drug efficacy.
Additional material
Additional file 1: Table S1. List of primers used for real-time qPCR
Additional file 2: Figure S1. VDR is expressed in SKOV-3. Immunoblot
showing VDR is expressed in SKOV-3 and VDR levels do not change in
response to MT19c.
Additional file 3: Figure S2. Immunohistochemistry suggests tumors
are majority tumor cells with little invasion. A. H&E staining of naïve
tumor. B. CA-125 staining of a representative naïve tumor. C. CA-125
staining of a MT19C treated tumor.
Additional file 4: Table S2. List of genes down-regulated by MT19c.
Additional file 5: Table S3. List of genes up-regulated by MT19c.
Additional file 6: Figure S3. qPCR and microarray data correlate.
Pooling samples from the 16 day MT19C treated and naïve tumors
indicates that qPCR and microarray data agree on the direction of the
fold change upon MT19C treatment. Error bars are standard deviation.
Panels A, B, and C indicate fold range relative to calnexin and tumor
N8A. Panel D calculates the fold change of the array and qPCR data for
the three genes indicated. ABCA1 and PPARg were considered significant
in the microarray data.
Additional file 7: Figure S4. PPARg signaling mediates chemosensitivity.
A. Rosiglitazone also inhibits cisplatin in SKOV-3. Increasing concentration
of Rosiglitazone show a dose dependent increase in the number of cells
with cisplatin similar to the dose dependent effects observed with
MT19c. B. The PPAR g antagonist, GW9662, shows no significant effect on
MT19c efficacy in a dose response curve.
Additional file 8: Figure S5. Dose response curves of cisplatin(CDDP) in
the presence of Rosiglitazone (Rosi) in the six NCI-60 ovarian cancer cell
lines. The number of viable cells was determined by Wst-1 after four
days. Rosi inhibits CDDP in some lines (SKOV-3) while in others (OVCAR-3
and OVAR-5) Rosi supports CDDP induced cell death.
Additional file 9: Table S4. GSEA data of chromosome loci enriched in
MT19c treated tumors.
Additional file 10: Table S5. GSEA data of chromosome loci enriched in
naive tumors
Additional file 11: Figure S6. Global copy number views of SKOV3
xenografts. Heat maps of all > 2 fold copy number changes from Agilent
180 K CGH microarrays compared to pooled normal female DNA. Notice
the amplification on chromosome 17 which includes ERBB2. The
genome has relatively few aberrations compared to other ovarian cancer
cell lines and many ovarian tumors. Red indicates a copy number gain
and blue indicates a copy number loss.
Additional file 12: Table S6. List of genes used to define the copy
number aberration gene set.
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